Gilead Sciences, Inc. (GILD)
NASDAQ: GILD · Real-Time Price · USD
92.57
+1.48 (1.62%)
At close: Dec 20, 2024, 4:00 PM
92.15
-0.42 (-0.45%)
After-hours: Dec 20, 2024, 6:57 PM EST
Gilead Sciences Product Revenue by Segment
History
| Date | HIV | Oncology | Liver Disease | Veklury | Other |
|---|---|---|---|---|---|
| Sep 30, 2024 | 18.85B | 3.21B | 2.99B | 2.18B | 906.00M |
| Jun 30, 2024 | 18.45B | 3.16B | 2.97B | 2.13B | 921.00M |
| Mar 31, 2024 | 18.33B | 3.05B | 2.85B | 2.17B | 884.00M |
| Dec 31, 2023 | 18.18B | 2.93B | 2.78B | 2.19B | 859.00M |
| Sep 30, 2023 | 18.26B | 2.78B | 2.79B | 2.47B | 910.00M |
| Jun 30, 2023 | 18.08B | 2.59B | 2.87B | 2.75B | 894.00M |
| Mar 31, 2023 | 17.68B | 2.39B | 2.84B | 2.94B | 907.00M |
| Dec 31, 2022 | 17.19B | 2.14B | 2.80B | 3.91B | 944.00M |
| Sep 30, 2022 | 16.96B | 1.88B | 2.76B | 4.26B | 942.00M |
| Jun 30, 2022 | 16.66B | 1.63B | 2.65B | 5.26B | 987.00M |
| Mar 31, 2022 | 16.37B | 1.41B | 2.76B | 5.64B | 1.02B |
| Dec 31, 2021 | 16.32B | 1.25B | 2.85B | 5.57B | 1.03B |
Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.